In the latest example of the life science sector's appeal to alt players, T-cell therapy specialist Neogene Therapeutics raised $110 million in a Series A round co-led by private equity firms Jeito Capital and Ecor1 Capital, along with British healthcare trust Syncona.
Neogene's research, which is still in the preclinical stage, aims to identify neoantigen specific T-cell receptor genes that will subsequently be engineered T cell therapies for solid tumors. T cell treatments are part of the cancer immunotherapy . . .
Continue Reading
Unlock this article instantly, along with the rest of our premium content and benefits including daily/weekly/monthly newsletters.
Monthly
$30
A pay-as-you-go plan to get you started
→ Instantly unlock all new and archived articles
→ Daily, weekly and monthly e-mail newsletters
→ Access to the weekly AW Deal Watch by AW Research
Annual
$300
Required for access to AW Research
Get more for less - 20% discount over monthly
→ Everything in Monthly PLUS:
→ Access to articles and data from AW Research
→ AW Annual Investor Compendium – our comprehensive guide to investor activity, with a ranking of the most active investors for the year and profiles of the top global allocators
